PAUL CORN to Antibodies, Monoclonal
This is a "connection" page, showing publications PAUL CORN has written about Antibodies, Monoclonal.
Connection Strength
0.175
-
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
Score: 0.077
-
Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst. 2011 Nov 16; 103(22):1665-75.
Score: 0.041
-
Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol. 2009 Sep 01; 27(25):4076-81.
Score: 0.035
-
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor). J Immunother Cancer. 2023 03; 11(3).
Score: 0.023